

Hamilton Regional Laboratory Medicine Program - HRLMP (effective at Hamilton Health Sciences, St. Joseph's Hospital and Associated Health Care Facilities)			
Initial Issue Date: Revision Date:	Administration Guidelines	Section: Laboratory Medicine Sub-Section: <i>Transfusion Medicine</i>	
Title: VARICELLA - ZOSTER IMMUNE GLOBULIN (Human)		Document Number:	
Approved By: <i>Director, Laboratory Medicine Chair, Regional Transfusion Medicine Committee Head, Transfusion Medicine, HRLMP Manager, Transfusion Medicine, HRLMP Technical Specialist, Transfusion Medicine, HRLMP Chief of Nursing Practice, Hamilton Health Sciences Chief of Nursing Practice, St Joseph's Healthcare</i>		Page 1 of 3	

- 1.0 **Purpose:** To Establish the Indications and Administration of Varicella-Zoster (VZ) Immune Globulin (VZIG)
- 2.0 **Scope:** All patient care areas across HHS and St. Joseph's Healthcare
- 3.0 **Definitions:** VZIG: is prepared from adult human plasma that contains high titres of varicella-zoster antibodies intended for passive immunization of susceptible immuno-deficient children after exposure to varicella (chicken pox).

Other Names: VZIG (Human)	Date Approved:	Pages: 1 of 3
----------------------------------	-----------------------	----------------------

<p>INDICATIONS:</p> <ul style="list-style-type: none"> - Post-exposure prophylaxis against VZ infection in an immunocompromised patient - Children susceptible include those with: <ul style="list-style-type: none"> - Primary immune deficiency disorders - Neoplastic diseases - Recipients of immunosuppressive doses of steroids, antimetabolites or other immunosuppressive treatment regimens - Newborns of mothers with recent chicken pox less than 5 days before birth or 48 hours after birth - Also indicated in immunocompromised adults 																								
<p>DOSAGE:</p> <ul style="list-style-type: none"> - Injection should occur within 96 hours of presumed exposure to varicella-zoster - Recommended dose: <table style="margin-left: 40px;"> <thead> <tr> <th><u>Weight (Kg)</u></th> <th><u>Units</u></th> <th><u>Units</u></th> <th><u>Number of Vials</u></th> </tr> </thead> <tbody> <tr> <td>0 - 10</td> <td>125</td> <td>1</td> <td></td> </tr> <tr> <td>10 - 20</td> <td>250</td> <td>2</td> <td>vials of 125 units</td> </tr> <tr> <td>20 - 30</td> <td>375</td> <td>3</td> <td>vials of 125 units</td> </tr> <tr> <td>30 - 40</td> <td>500</td> <td>4</td> <td>vials of 125 units</td> </tr> <tr> <td>Over 40</td> <td>625</td> <td>5</td> <td>or 1 vial of 625 if available</td> </tr> </tbody> </table> 	<u>Weight (Kg)</u>	<u>Units</u>	<u>Units</u>	<u>Number of Vials</u>	0 - 10	125	1		10 - 20	250	2	vials of 125 units	20 - 30	375	3	vials of 125 units	30 - 40	500	4	vials of 125 units	Over 40	625	5	or 1 vial of 625 if available
<u>Weight (Kg)</u>	<u>Units</u>	<u>Units</u>	<u>Number of Vials</u>																					
0 - 10	125	1																						
10 - 20	250	2	vials of 125 units																					
20 - 30	375	3	vials of 125 units																					
30 - 40	500	4	vials of 125 units																					
Over 40	625	5	or 1 vial of 625 if available																					

SUPPLIED:

- Vial 125 units with 2.0 mL volume (or less)
- Vial 625 units with 10.0 mL volume (or less)
- Do not use past expiration date

RECONSTITUTION AND STABILITY:

- Product should be stored between 2 and 8°C
- Do not freeze

ADMINISTRATION:

METHOD	WHO/WHERE	DILUTION	HOW TO ADMINISTER	INFUSION PUMP	PRECAUTIONS AND MONITORING
IV PUSH	N/A	N/A	N/A	N/A	N/A
MINIBAG/ BURETROL	N/A	N/A	N/A	N/A	N/A
PRIMARY IV BAG	N/A	N/A	N/A	N/A	N/A
IM or SC	RN	No	- Administer intramuscularly, 2.5 mL into single site	No	- Observe and monitor for adverse reaction

COMPATIBILITIES/INCOMPATIBILITIES:

- Antibodies present in immune globulin preparations may interfere with the immune response to live virus vaccines such as measles, mumps and rubella; therefore, vaccination should be deferred until approximately three months after administration of VZIG
- Persons who received VZIG within 14 days of live virus vaccination should be revaccinated three months later

ADVERSE EFFECTS:

- It is not known whether administration of VZIG to a pregnant woman can cause fetal harm
- Usual adverse reaction is local discomfort at the injection site, pain, redness or swelling of the injection site (may occur in 1 of 100 patients)
- Less frequently, gastrointestinal symptoms malaise, headache, rash and respiratory symptoms (1 in 500 patients)
- Severe reactions such as angioneurotic edema and anaphylactic shock are rare

MANAGEMENT OF ADVERSE EFFECTS:

- Notify physician
- Notify Transfusion Medicine
- Epinephrine should be available to treat acute reactions

NOTES:

- Manufactured by Massachusetts Public Health Biologic Laboratories (a Division of the State Laboratory Institute), Department of Public Health, The Commonwealth of Massachusetts, Boston, Massachusetts
- Distributed by Canadian Blood Service

Documentation:

Issue transfuse sheets or requisition with lot number must be included in patient's chart. Written consent for transfusion must be obtained prior to administration.

References

Package Insert- Varicella-Zoster Immune Globulin (Human) Massachusetts Public Health Biologic Laboratories, January 1, 1986.
Blood Transfusion Therapy, A Physician's Handbook, 7th edition American Association of Blood Banks, 2002

Developed By In Consultation With

Transfusion Medicine Operations Group
Pediatric Clinical Nurse Educators

REVIEW DATES:

REVISION DATES: